Your 40s are not a deadline. They are an opportunity. For many people, this is the decade when changes in muscle mass, bone health, cardiovascular risk, metabolism and reproductive hormones begin to become more relevant—even when day-to-day life still feels completely normal. That is what makes this period so important. Many of the conditions that become major problems later in life develop gradually and silently. By the time symptoms appear, the underlying process may have been developing for years. The goal isn't to become obsessed with aging. It's to get ahead of it. Here are five areas worth paying attention to in your 40s. 1. Screen Smarter, Not Just More Preventive healthcare isn't about ordering every test available. It's about knowing which risks apply to you and making sure appropriate screening happens at the right time. Cancer is an obvious example. The most useful screening strategy depends on factors including: - Age - Sex - Family history - Previous screening results - Personal medical history - Smoking history - Genetic risk - Symptoms There isn't one universal "40s cancer screen." For example, current U.S. Preventive Services Task Force guidance recommends biennial mammography for women aged 40–74 at average risk, while colorectal cancer screening generally begins at 45 for average-risk adults. Other screening recommendations have completely different age ranges and criteria. That is why "screen smarter" is better advice than simply "screen everything." The objective is to identify meaningful risks while they are still manageable—not to turn healthy people into a collection of abnormal test results. And screening should always be individualized with a healthcare professional, particularly when family history or other risk factors change the equation. 2. Start Treating Bone as a Training Adaptation Bone is living tissue. It responds to mechanical loading. That makes resistance training one of the most interesting tools available for maintaining skeletal strength as we age.

The accidental-exposure question, reexamined GLP-1 medications have transformed the treatment landscape for obesity and type 2 diabetes. They have also created a new question for people who may become pregnant: What happens if someone is taking a GLP-1 medication when they conceive or discovers a pregnancy before realizing they were pregnant? For years, the answer has been dominated by caution. Human pregnancy data were limited, while animal studies raised concerns about potential developmental effects. As a result, product labeling and clinical guidance have generally advised against GLP-1 receptor agonist use during pregnancy. But the evidence base is changing. Several systematic reviews and meta-analyses published in 2026 have now examined tens of thousands of pregnancies involving exposure to GLP-1 receptor agonists before conception, around conception, or during pregnancy. And while these studies do not establish that GLP-1 medications are safe during pregnancy, the emerging data are more reassuring than some earlier concerns might have suggested. That distinction is crucial. The new evidence is primarily useful for answering a different question: If someone was inadvertently exposed to a GLP-1 medication early in pregnancy, does that exposure necessarily mean a major pregnancy complication or birth defect will occur? So far, the evidence does not suggest that it does. The largest question: What does the new evidence show? A 2026 systematic review and meta-analysis published in JACC: Advances examined four observational studies involving 36,963 pregnancies. The researchers compared pregnancies involving GLP-1 receptor agonist exposure with pregnancies involving other antidiabetic therapies. Their findings were notable. GLP-1 receptor agonist exposure was associated with: - 28% lower odds of adverse maternal outcomes overall - 34% lower odds of preterm birth - No statistically significant increase in major congenital anomalies - No significant increase in overall adverse fetal outcomes

What if peptides didn't need water to remain structurally intact? That question sounds almost absurd when you consider Venus. Its surface is a furnace. Its atmosphere is dominated by carbon dioxide. And its clouds contain concentrated sulfuric acid. Yet new research from scientists at MIT suggests that short peptides can remain intact and adopt stable three-dimensional structures in an environment containing 98% sulfuric acid. The finding doesn't prove that life exists on Venus. It doesn't show that Venusian organisms are using peptides. And it certainly doesn't mean peptides are somehow indestructible. What it does demonstrate is much more scientifically interesting: Some complex biological molecules may be capable of maintaining structure in environments that scientists previously considered extraordinarily hostile to them. That could broaden the places researchers consider when searching for chemistry associated with life. Venus Is About as Far From Earth-Like as You Can Get Venus is often called Earth's sister planet because the two worlds are similar in size and composition. But the similarities largely stop there. Venus has an extremely hot surface and an atmosphere dominated by carbon dioxide. Its cloud layer contains droplets of sulfuric acid, creating an environment vastly different from the aqueous environments in which terrestrial biology operates. Yet the clouds themselves are more intriguing than the surface. At certain altitudes, temperatures and pressures are considerably less extreme than at the surface. That has led some astrobiologists to ask an unusual question: Could Venus' clouds provide an environment where some form of chemistry associated with life could persist? The latest peptide research doesn't answer that question. But it adds another important piece of evidence to the puzzle. The New Discovery: Peptides Survived 98% Sulfuric Acid The study, published in Proceedings of the National Academy of Sciences, examined three peptides in highly concentrated sulfuric acid.

Something significant happened in Washington on September 1, 2026. Congresswoman Nancy Mace introduced the PEPTIDES for Veterans Act, legislation that would direct the Department of Veterans Affairs to formally study peptide-based therapies and their potential applications for veterans. The bill doesn't declare peptides proven. It doesn't approve experimental treatments. And it doesn't immediately give veterans access to peptide therapy. What it does is arguably more interesting: It asks the VA to investigate the subject directly. That could represent an important shift in how experimental peptide therapies are discussed at the federal level. For years, peptide discussions have largely lived in the worlds of research, bodybuilding, biohacking, longevity and online wellness communities. Now the conversation has reached Congress. What Is the PEPTIDES for Veterans Act? The legislation is officially called the Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act, or the PEPTIDES for Veterans Act. It was introduced in the House on September 1, 2026, by Representative Nancy Mace of South Carolina as H.R. 10212. The bill has been referred to the House Committee on Veterans' Affairs. Its central objective is straightforward: Direct the VA to investigate the potential benefits, safety and therapeutic applications of peptide-based therapies for veterans receiving VA care. That's an important distinction. The legislation isn't saying: "Peptides work." It's effectively saying: "There is enough interest in this area to justify formally studying the evidence." That is a very different claim. And scientifically, it's the more responsible one. What Would the VA Actually Have to Do? Under the proposed legislation, the VA would first conduct a comprehensive review of existing regulations and guidance surrounding peptide therapies. The bill then calls for an 18-month study examining peptide-based therapies across several potential areas, including:

Your body has its own built-in antimicrobial defense system. Long before antibodies and other parts of the adaptive immune response become fully engaged, the innate immune system is already working to recognize and respond to potential threats. One of the molecules involved in that first line of defense is LL-37. LL-37 is a naturally occurring human host-defense peptide and the only known human member of the cathelicidin family. It has been detected in tissues exposed to the outside environment, including the skin, gastrointestinal tract and respiratory system, and is produced by several types of immune and epithelial cells. What makes LL-37 particularly interesting is that its biological activity appears to extend far beyond simply damaging microbes. Researchers have investigated its potential roles in: - Antibacterial defense - Antifungal activity - Antiviral responses - Immune-cell recruitment - Inflammatory signaling - Cell migration - Angiogenesis - Wound repair That combination has made LL-37 one of the more fascinating host-defense peptides in experimental research. But there is an important distinction throughout this article: LL-37's biological activity is well documented in experimental research. That does not mean LL-37 is an approved treatment for infections, wounds or any other medical condition. What Exactly Is LL-37? LL-37 is a 37-amino-acid antimicrobial peptide derived from a larger precursor protein called human cathelicidin antimicrobial protein 18, or hCAP18. It belongs to a broader group of molecules known as host-defense peptides (HDPs). These peptides are interesting because they can perform multiple biological functions at the same time. They can interact directly with microorganisms while also influencing the cells and signaling pathways involved in the host's immune response. That makes LL-37 less like a conventional single-purpose antimicrobial molecule and more like a multifunctional component of innate immunity.